This company has been acquired
Concert Pharmaceuticals Future Growth
Future criteria checks 2/6
Key information
38.9%
Earnings growth rate
43.34%
EPS growth rate
| Biotechs earnings growth | 23.8% |
| Revenue growth rate | 54.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 06 Mar 2023 |
Recent future growth updates
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 96 | -69 | N/A | -86 | 2 |
| 12/31/2024 | 29 | -129 | N/A | -140 | 2 |
| 12/31/2023 | 18 | -137 | N/A | -78 | 3 |
| 12/31/2022 | 0 | -122 | N/A | N/A | 3 |
| 9/30/2022 | 32 | -127 | -110 | -110 | N/A |
| 6/30/2022 | 33 | -125 | -103 | -102 | N/A |
| 3/31/2022 | 33 | -95 | -67 | -67 | N/A |
| 12/31/2021 | 33 | -80 | -55 | -55 | N/A |
| 9/30/2021 | 1 | -66 | -45 | -45 | N/A |
| 6/30/2021 | 2 | -59 | -47 | -47 | N/A |
| 3/31/2021 | 8 | -77 | -72 | -72 | N/A |
| 12/31/2020 | 8 | -75 | -69 | -69 | N/A |
| 9/30/2020 | 8 | -73 | -68 | -68 | N/A |
| 6/30/2020 | 6 | -71 | -64 | -63 | N/A |
| 3/31/2020 | 0 | -77 | -66 | -65 | N/A |
| 12/31/2019 | 1 | -78 | -49 | -49 | N/A |
| 9/30/2019 | 1 | -79 | -50 | -49 | N/A |
| 6/30/2019 | 1 | -79 | -47 | -45 | N/A |
| 3/31/2019 | 1 | -73 | -40 | -37 | N/A |
| 12/31/2018 | 11 | -56 | -51 | -48 | N/A |
| 9/30/2018 | 11 | -41 | -41 | -39 | N/A |
| 6/30/2018 | 11 | 104 | 104 | 106 | N/A |
| 3/31/2018 | 11 | 104 | 104 | 105 | N/A |
| 12/31/2017 | 0 | 95 | 103 | 104 | N/A |
| 9/30/2017 | 0 | 89 | 98 | 99 | N/A |
| 6/30/2017 | 0 | -50 | -46 | -45 | N/A |
| 3/31/2017 | 0 | -50 | -45 | -44 | N/A |
| 12/31/2016 | 0 | -51 | -46 | -45 | N/A |
| 9/30/2016 | 10 | -38 | -33 | -33 | N/A |
| 6/30/2016 | 12 | -35 | N/A | -30 | N/A |
| 3/31/2016 | 15 | 19 | N/A | 20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNCE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CNCE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CNCE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CNCE's revenue (54.9% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: CNCE's revenue (54.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNCE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/07 22:10 |
| End of Day Share Price | 2023/03/03 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Concert Pharmaceuticals, Inc. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Esther Lannie Hong | Berenberg |
| Liisa Bayko | Citizens JMP Securities, LLC |